GSK poach­es new drug de­vel­op­ment chief Chris Cor­si­co from Boehringer, di­vid­ing R&D in­to two groups

Glax­o­SmithK­line is con­tin­u­ing its makeover in the ex­ec­u­tive team that runs its R&D group.

The phar­ma gi­ant tells me that Chris Cor­si­co, who had been chief med­ical of­fi­cer at the pri­vate Ger­man out­fit Boehringer In­gel­heim, is step­ping over to GSK as the head of drug de­vel­op­ment, putting him in a new, top po­si­tion for ham­mer­ing out the clin­i­cal plans that the phar­ma gi­ant is putting in­to place un­der R&D chief Hal Bar­ron. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.